- In January 2023, Ipsen entered into acquisition of Albireo, enhancing its rare disease portfolio with Bylvay (odevixibat), the first approved treatment for progressive familial intrahepatic cholestasis. This strategic move aims to accelerate growth in rare pediatric liver diseases, bolstering Ipsen’s market presence and expanding treatment options for underserved patients.
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 PIPELINE ANALYSIS - OBSERVATORY DATA
4.4 EPIDEMIOLOGY
5 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: REGULATIONS
5.1 REGULATION IN UNITED STATES: U.S. FOOD AND DRUG ADMINISTRATION (FDA)
5.1.1 REGULATION IN EUROPE: EUROPEAN MEDICINES AGENCY (EMA)
5.2 REGULATION IN ASIA-PACIFIC (JAPAN): PHARMACEUTICAL AND MEDICAL DEVICES AGENCY (PMDA)
5.3 MEDICAL DEVICE STANDARDS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF GENETIC DISORDERS
6.1.2 GROWING PEDIATRIC POPULATION
6.1.3 DEVELOPMENT OF NOVEL THERAPIES
6.2 RESTRAINTS
6.2.1 HIGH COST OF ADVANCED THERAPIES
6.2.2 LIMITED AVAILABILITY OF THERAPIES
6.3 OPPORTUNITIES
6.3.1 INCREASE IN PATIENT CARE AND SUPPORT SYSTEMS
6.3.2 INCREASE IN THE NUMBER OF COLLABORATIONS AND PARTNERSHIPS
6.4 CHALLENGES
6.4.1 LIMITED AWARENESS ABOUT THE DISORDER
6.4.2 LACK OF DRUG APPROVALS ASSOCIATED WITH THE DISORDER
7 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE
7.1 OVERVIEW
7.2 SESSILE
7.3 PEDUNCULATED
8 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 SURGERY
8.2.1 REMOVE THE TUMOR
8.2.2 LENGTHEN LIMBS
8.3 MEDICATION
8.3.1 HOSPITAL PHARMACIES
8.3.2 DRUGS STORES AND RETAIL PHARMACIES
8.3.3 ONLINE PHARMACIES
8.4 OTHERS
9 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS
9.1 OVERVIEW
9.2 X-RAY
9.2.1 SESSILE
9.2.2 PEDUNCULATED
9.3 COMPUTED TOMOGRAPHY (CT) SCAN
9.3.1 SESSILE
9.3.2 PEDUNCULATED
9.4 MAGNETIC RESONANCE IMAGING (MRI)
9.4.1 SESSILE
9.4.2 PEDUNCULATED
9.5 GENETIC TESTS
9.5.1 SESSILE
9.5.2 PEDUNCULATED
9.6 OTHERS
9.6.1 SESSILE
9.6.2 PEDUNCULATED
10 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE
10.1 OVERVIEW
10.2 LEGS
10.3 ARMS
10.4 SHOULDERS
10.5 PELVIS
10.6 FINGERS
10.7 TOES
11 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP
11.1 OVERVIEW
11.2 PEDIATRIC
11.3 ADULT
12 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITAL
12.2.1 PRIVATE
12.2.2 GOVERNMENT
12.3 SPECIALTY CLINICS
12.4 AMBULATORY SURGICAL CENTERS
12.5 OTHERS
13 NORTH AMERICA MULTIPLE HEREDITY EXOSTOSIS MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S
13.1.2 CANADA
13.1.3 MEXICO
14 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT ANALYSIS
16 COMPANY PROFILES
16.1 BAYERS AG
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT UPDATES
16.2 HALEON GROUP OF COMPANIES
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 BASF
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT UPDATES
16.4 VIATRIS INC.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT UPDATES
16.5 ACTIZAPHARMA
16.5.1 COMPANY SNAPSHOT
16.5.2 PRODUCT PORTFOLIO
16.5.3 RECENT UPDATES
16.6 ADVACARE PHARMA
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT UPDATES
16.7 AUROBINDO PHARMA
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT TABLETS
16.8 HALEON GROUP OF COMPANIES
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT UPDATES
16.9 IPSEN BIOPHARMACEUTICALS, INC.
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT UPDATES
16.1 MALLINCKRODT
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT UPDATES
16.11 TEVA PHARMACEUTICAL INDUSTRIES LTD.
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT UPDATES
16.12 TAJ PHARMACEUTICALS LIMITED
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT UPDATES
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 PIPELINE ANALYSIS - OBSERVATORY DATA
TABLE 2 PIPELINE ANALYSIS - INTERVENTIONAL DATA
TABLE 3 SALES DATA - 2024
TABLE 4 SALES DATA - 2023
TABLE 5 SALES DATA - 2022
TABLE 6 SALES DATA - 2021
TABLE 7 SALES DATA - 2020
TABLE 8 SALES DATA - 2019
TABLE 9 SALES DATA - 2018
TABLE 10 COST OF PALOVAROTENE
TABLE 11 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 12 NORTH AMERICA SESSILE IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 13 NORTH AMERICA PEDUNCULATED IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 15 NORTH AMERICA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 16 NORTH AMERICA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 17 NORTH AMERICA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 18 NORTH AMERICA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 19 NORTH AMERICA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 20 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 21 NORTH AMERICA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 22 NORTH AMERICA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 23 NORTH AMERICA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 24 NORTH AMERICA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 25 NORTH AMERICA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 26 NORTH AMERICA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 27 NORTH AMERICA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 28 NORTH AMERICA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 29 NORTH AMERICA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 30 NORTH AMERICA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 31 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 32 NORTH AMERICA LEGS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 33 NORTH AMERICA ARMS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 34 NORTH AMERICA SHOULDERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 35 NORTH AMERICA PELVIS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 NORTH AMERICA FINGERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 37 NORTH AMERICA TOES IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 38 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 39 NORTH AMERICA PEDIATRIC IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 40 NORTH AMERICA ADULT IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 41 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 42 NORTH AMERICA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 43 NORTH AMERICA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 44 NORTH AMERICA SPECIALTY CLINICS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 45 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 46 NORTH AMERICA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 47 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 48 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 49 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 50 NORTH AMERICA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 51 NORTH AMERICA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 52 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 53 NORTH AMERICA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 NORTH AMERICA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 55 NORTH AMERICA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 56 NORTH AMERICA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 57 NORTH AMERICA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 58 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 59 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 60 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 61 NORTH AMERICA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 62 U.S. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 63 U.S. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 64 U.S. SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 U.S. MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 66 U.S. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 67 U.S. X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 U.S. COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 69 U.S. MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 70 U.S. GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 71 U.S. OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 72 U.S. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 73 U.S. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 74 U.S. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 75 U.S. HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 CANADA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 77 CANADA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 78 CANADA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 79 CANADA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 80 CANADA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 81 CANADA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 82 CANADA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 83 CANADA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 84 CANADA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 85 CANADA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 86 CANADA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 87 CANADA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 88 CANADA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 89 CANADA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 MEXICO MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 91 MEXICO MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 92 MEXICO SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 MEXICO MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 94 MEXICO MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 95 MEXICO X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 96 MEXICO COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 97 MEXICO MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 98 MEXICO GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 99 MEXICO OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 100 MEXICO MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 101 MEXICO MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 102 MEXICO MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 103 MEXICO HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
List of Figure
FIGURE 1 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 PRODUCT LIFELINE CURVE
FIGURE 9 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: DBMR MARKET POSITION GRID
FIGURE 10 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: SEGMENTATION
FIGURE 12 EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 TWO SEGMENTS COMPRISE THE NORTH AMERICA MULTIPLE HEREDITY EXOSTOSIS MARKET, BY TYPE
FIGURE 15 RISING PREVALENCE OF GENETIC DISORDERS IS DRIVING THE GROWTH OF THE NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET FROM 2024 TO 2031
FIGURE 16 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET IN 2024 AND 2031
FIGURE 17 MARKET OVERVIEW
FIGURE 18 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, 2023
FIGURE 19 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 20 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 21 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, 2023
FIGURE 23 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, 2024-2031 (USD THOUSAND)
FIGURE 24 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 25 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 26 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, 2023
FIGURE 27 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, 2024-2031 (USD THOUSAND)
FIGURE 28 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, CAGR (2024-2031)
FIGURE 29 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, LIFELINE CURVE
FIGURE 30 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, 2023
FIGURE 31 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, 2024-2031 (USD THOUSAND)
FIGURE 32 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, CAGR (2024-2031)
FIGURE 33 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, LIFELINE CURVE
FIGURE 34 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, 2023
FIGURE 35 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, 2024-2031 (USD THOUSAND)
FIGURE 36 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, CAGR (2024-2031)
FIGURE 37 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 38 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, 2023
FIGURE 39 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 40 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, CAGR (2024-2031)
FIGURE 41 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 42 NORTH AMERICA MULTIPLE HEREDITY EXOSTOSIS MARKET: SNAPSHOT (2023)
FIGURE 43 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: COMPANY SHARE 2023 (%)
